Histone Deacetylase Inhibitors and Mithramycin A Impact a Similar Neuroprotective Pathway at a Crossroad between Cancer and Neurodegeneration

Mithramycin A (MTM) and histone deacetylase inhibitors (HDACi) are effective therapeutic agents for cancer and neurodegenerative diseases. MTM is a FDA approved aureolic acid-type antibiotic that binds to GC-rich DNA sequences and interferes with Sp1 transcription factor binding to its target sites...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Sleiman, Sama F., Berlin, Jill, Basso, Manuela, S.Karuppagounder, Saravanan, Rohr, Jürgen, Ratan, Rajiv R.
Format: Artigo
Sprache:Inglês
Veröffentlicht: MDPI 2011
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3349345/
https://ncbi.nlm.nih.gov/pubmed/22582024
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ph4081183
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge